

Iastrebner M, Flores G, Nucifora E, Alfonso G, Barcala V, Garcia Rivello H, Kornblihtt L, Rosenheim M, Benasayag S, Belli C. Grupo de Estudio de Síndromes Mielodisplásicos de la Sociedad Argentina de Hematología

Introduction

The International Prognostic Scoring System (IPSS) has recently been refined with new clinical features like marrow blast percentage, depth of cytopenia, and more differentiated cytogenetic subgroups (IPSS-R).

Objective

The objective of this study is to examine the prognostic impact of IPSS-R on a group of patients under epigenetic treatment.

Materials and Methods

Retrospective study (real life)
Period: 5 years (2007 – 2012)

Inclusion criteria:

- Adult MDS consecutive patients who had received hypomethylating treatment at any time of follow-up

Exclusion criteria:

- Patients on disease-modifying drugs, secondary MDS, and proliferative CMML

Treatment:

- Azacitidine 75 mg/m², 7 days
- Decitabine 20 mg/m², 5 days

Parameters to evaluate:

- Time from diagnosis to treatment (TTT)
- Time to leukemia transformation (LFS)
- Overall survival (OS)
- Time from treatment to last follow up or death
- Number of cycles received
- Overall response rate (ORR)


Data were analyzed using:

- Kaplan-Meier, log-rank, Kendall's tests

Results

Stratification	IPSS			
IPSS-R (n = 65)	L (8)	INT-1 (34)	INT-2 (16)	H (7)
L + VL (18)	8	10	--	--
IM (21)	--	19	2	--
H + VH (26)	--	5	14	7

Stratification (IPSS → IPSS-R)	19/26 (73%) INT 1 / 2 → H and VH (Kendall's tau=0,338)
Number of cycles	7 (R 1 – 27)
ORR	41% (CR 14%, PR 10%, HI 17%) SD 8% and NR 51%
AML Progression	31%
Mortality Rate	52%




IPSS-R				
Month	L + VL	I	H + VH	
OS	44	40	20	p = 0,043
TTT	14	4	4	p = 0,051
LFS	43	10	19	p = 0,13

Results

Study Population	n = 65
Age (median)	68 (R 29 – 89)
Gender	Male 72%

WHO CLASSIFICATION



Conclusions

- Although the **number of patients** was relatively small and the population **heterogeneous, stratification and refinement of IPSS-R** enabled us to identify a statistical difference in terms of **OS** (p=0,043) and a significant tendency in **TTT** (p=0,051)
- No significant correlation was found between IPSS-R subgroups and ORR, LFS and time after treatment.

References

- Greenberg et al. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome. Blood, 2012
- Lamarque M et al. The Revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. Blood, 2012
- Bressia M et al. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. Ann Hematol, 2012